A Novel UHPLC-MS/MS Method for the Quantification of Seven Opioids in Different Human Tissues
-
Published:2023-06-19
Issue:6
Volume:16
Page:903
-
ISSN:1424-8247
-
Container-title:Pharmaceuticals
-
language:en
-
Short-container-title:Pharmaceuticals
Author:
Manca Alessandra1ORCID, De Nicolò Amedeo1ORCID, De Vivo Elisa Delia1ORCID, Ferrara Micol2ORCID, Oh Sharon3ORCID, Khalili Sahar3, Higgins Niamh3, Deiss Robert G.3, Bonora Stefano2, Cusato Jessica1ORCID, Palermiti Alice1ORCID, Mula Jacopo14ORCID, Gianella Sara3, D’Avolio Antonio14ORCID
Affiliation:
1. Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Corso Svizzera, 164, 10149 Turin, Italy 2. Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, 10149 Turin, Italy 3. San Diego Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA 92037, USA 4. CoQua Lab s.r.l., 10149 Turin, Italy
Abstract
Background: Opioids are considered the cornerstone of pain management: they show good efficacy as a first-line therapy for moderate to severe cancer pain. Since pharmacokinetic/pharmacodynamic information about the tissue-specific effect and toxicity of opioids is still scarce, their quantification in post-mortem autoptic specimens could give interesting insights. Methods: We describe an ultra-high-performance liquid chromatography coupled with tandem mass spectrometry method for the simultaneous quantification of methadone, morphine, oxycodone, hydrocodone, oxymorphone, hydromorphone and fentanyl in several tissues: liver, brain, kidney, abdominal adipose tissue, lung and blood plasma. The presented method has been applied on 28 autoptic samples from different organs obtained from four deceased PLWH who used opioids for palliative care during terminal disease. Results: Sample preparation was based on tissue weighing, disruption, sonication with drug extraction medium and a protein precipitation protocol. The extracts were then dried, reconstituted and injected onto the LX50 QSight 220 (Perkin Elmer, Milan, Italy) system. Separation was obtained by a 7 min gradient run at 40 °C with a Kinetex Biphenyl 2.6 µm, 2.1 × 100 mm. Concerning the analyzed samples, higher opioids concentrations were observed in tissues than in plasma. Particularly, O-MOR and O-COD showed higher concentrations in kidney and liver than other tissues (>15–20 times greater) and blood plasma (>100 times greater). Conclusions: Results in terms of linearity, accuracy, precision, recovery and matrix effect fitted the recommendations of FDA and EMA guidelines, and the sensitivity was high enough to allow successful application on human autoptic specimens from an ethically approved clinical study, confirming its eligibility for post-mortem pharmacological/toxicological studies.
Funder
NIH P01 fund NIDA “Avenir”
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference42 articles.
1. Cancer pain management: Safe and effective use of opioids;Bruera;Am. Soc. Clin. Oncol. Educ. Book.,2015 2. Opioid receptors;McDonald;Contin. Educ. Anaesth. Crit. Care Pain,2005 3. Opioid pharmacology;Trescot;Pain. Physician,2008 4. Opioid receptors;Waldhoer;Annu. Rev. Biochem.,2004 5. CDC (2023, April 18). Clinical Practice Guideline for Prescribing Opioids for Pain—United States, Available online: https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm?s_cid=rr7103a1.htm_w.
|
|